ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 69 filers reported holding ALIGOS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $754,931 | -21.8% | 1,010,617 | +1.6% | 0.00% | – |
| Q2 2023 | $965,866 | +8.7% | 994,712 | -2.2% | 0.00% | – |
| Q1 2023 | $888,579 | -8.0% | 1,016,681 | +0.3% | 0.00% | – |
| Q4 2022 | $965,761 | -19.5% | 1,013,496 | -7.0% | 0.00% | – |
| Q3 2022 | $1,199,000 | -6.8% | 1,089,992 | +2.6% | 0.00% | – |
| Q2 2022 | $1,286,000 | -53.4% | 1,062,672 | -17.3% | 0.00% | – |
| Q1 2022 | $2,762,000 | -83.1% | 1,284,763 | -6.6% | 0.00% | – |
| Q4 2021 | $16,320,000 | -17.5% | 1,374,914 | +7.8% | 0.00% | – |
| Q3 2021 | $19,779,000 | -1.3% | 1,275,215 | +29.7% | 0.00% | – |
| Q2 2021 | $20,045,000 | +43.4% | 983,296 | +59.9% | 0.00% | – |
| Q1 2021 | $13,980,000 | -17.2% | 614,757 | +0.7% | 0.00% | – |
| Q4 2020 | $16,886,000 | – | 610,704 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
| TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
| Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
| Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
| EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
| HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
| Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
| HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |